LLY vs MAR: Which Is the Better Buy?
Side-by-side comparison of Eli Lilly and Company and Marriott International, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-26.
Eli Lilly and Company · Healthcare
$1,183.72
+2.1% upside to fair value
Med Conviction
Grade B
High Quality
VS
Marriott International, Inc. · Consumer Cyclical
$334.97
+20.6% upside to fair value
Med Conviction
Grade C
QuantHub Verdict
MAR has more upside to fair value
(+20.6%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
LLY |
MAR |
| Current Price |
$1,183.72 |
$334.97 |
| Fair Value Estimate |
$1,208.00 |
$403.81 |
| Upside to Fair Value |
+2.1%
|
+20.6%
|
| Market Cap |
$1,114.8B |
$87.3B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
26.8x
|
22.2x
|
| Price / Sales |
14.0x
|
3.2x
|
| Price / FCF |
52.7x
|
28.7x
|
| Revenue Growth YoY |
+47.7%
|
+4.8%
|
| Gross Margin |
83.4%
|
20.2%
|
| Operating Margin |
49.7%
|
15.8%
|
| Return on Equity |
92.6%
|
-66.7%
|
| Dividend Yield |
0.57% |
0.84% |
| FCF Yield |
1.9%
|
3.48%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Eli Lilly is a global pharmaceutical company whose incretin franchise, led by Mounjaro and Zepbound, has become the dominant growth engine in diabetes and obesity care. The business quality is high: TTM gross margin is 83.4%, TTM operating margin is 49.7%, TTM net margin is 33.5%, and ROE is 92.6%, while revenue grew 47.7% and earnings grew 25.3% in the most recent quarter on a year-over-year bas…
Marriott International is a global asset-light hotel franchisor and manager whose 10,082-property, 1.814 million-room system, 629,000-room development pipeline, broad brands, and more than 295 million Bonvoy members support durable fee-led economics. Business quality is tempered by cyclicality, competitive owner incentives, and $16.915 billion of debt, while reported ROE is negative 66.7%. In the…
Accumulation Zones
| Metric |
LLY |
MAR |
| Zone Low |
$906.00 |
$302.86 |
| Zone High |
$1,026.80 |
$343.24 |
| In Buy Zone? |
No
|
Yes
|